Drug intelligence / Profile preview

E-B-FAHF-2

Development stage
Phase 2
Lead developer
Icahn School of Medicine
Administration
Oral
01

Overview

**E-B-FAHF-2** is an oral, enhanced ethyl acetate/butanol-purified version of Food Allergy Herbal Formula-2, a standardized nine-herb traditional Chinese medicine-derived botanical formula based on Wu Mei Wan. It is being developed as an immunomodulatory botanical drug for food allergy and mild-to-moderate Crohn's disease. Preclinical and ex vivo studies indicate suppression of NF-κB-associated inflammatory signaling and reduced production of pro-inflammatory cytokines including TNF-α, IL-1β, IL-6, IL-17, IFN-γ, and IL-12 in Crohn's disease models and patient-derived samples. It has been evaluated orally in Phase 2 food-allergy studies, including as an adjunct to omalizumab-facilitated multi-allergen oral immunotherapy, and is in a Phase 1 study in mild-to-moderate Crohn's disease. ([clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03992469))

Other names
Enhanced-Butanol purified-Food Allergy Herbal Formula-2Ethyl acetate and butanol purified Food Allergy Herbal Formula-2
02

Targets

NF-κB

Beyond the preview

Go deeper on E-B-FAHF-2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on E-B-FAHF-2.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call